Daiichi Sankyo Gets Japanese Approval For Rezaltas Combination Tablets
Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker). It also contains azelnidipine (Calblock), a long-acting CCB (calcium channel
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.